Neurocrine Biosciences has agreed to acquire Soleno Therapeutics in a $2.9 billion all-cash transaction, reinforcing its strategic expansion into endocrinology and rare disease treatments. Under the terms of the agreement, Neurocrine will pay $53 per share — representing a premium